Assessment of the immune system in 55 Iranian patients with vitiligo

Journal of the European Academy of Dermatology and Venereology

Volumn 19, Issue 6, 2005, Pages 706-711

  Farrokhi, S ^a,b,c   Hojjat Farsangi, M ^a   Noohpisheh, M K ^a   Tahmasbi, R ^a   Rezaei, N ^b  

^a Boushehr University of Medical Sciences   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antinuclear antibody; Autoimmune; Melanocyte; Pathogenesis; Vitiligo

Indexed keywords

ANTINUCLEAR ANTIBODY; CELL ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; MELANOCYTIC ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE SYSTEM; IMMUNODIFFUSION; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHOOL CHILD; VITILIGO;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTINUCLEAR; CHI-SQUARE DISTRIBUTION; CHILD; COMPLEMENT C3; COMPLEMENT C4; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNODIFFUSION; IMMUNOGLOBULIN M; IRAN; MALE; MELANOCYTES; MIDDLE AGED; VITILIGO;

EID: 28544438015     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2005.01295.x     Document Type: Article

References (29)

1. van den Wijngaard R, Wankowicz-Kalinska A, Pals S, Weening J, Das P. Autoimmune melanocyte destruction in vitiligo. Lab Invest 2001; 81: 1061-1067.
2. Gauthier Y, Cario M, Taieb A. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment Cell Res 2003; 16: 322-332.
3. Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003; 16: 90-100.
4. Le Poole IC, Das PK, van den Wijngaard RM, Bos JD, Westerhof W. Review of the etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol 1993; 2: 145-153.
5. Lerner A. Vitiligo. J Invest Dermatol 1995; 32: 285-291.
6. Kovacs SO. Vitiligo. J Am Acad Dermatol 1998; 38: 647-666.
7. Kemp EH, Waterman EA, Weetman AP. Autoimmune aspects of vitiligo. Autoimmunity 2001; 34: 65-77.
8. Bystryn JC. Serum antibodies in vitiligo patients. Clin Dermatol 1989; 7: 136-145.
9. van den Wijngaard R, Wankowicz-Kalinska A, Le Poole C et al. Local immune response in skin of generalized vitiligo patients. Lab Invest 2000; 80: 1299-1309.
10. Yu HS, Kao CH, Yu CL. Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental-type vitiligo. J Invest Dermatol 1993; 100: 823-828.
11. Harning R, Cui J, Bystryn JC. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 1991; 97: 1078-1080.
12. Gilhar A, Zelickson B, Ulman Y, Etzioni A. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol 1995; 105: 683-686.
13. Zetting G, Tanew A, Fischer G et al. Autoimmune diseases in vitiligo: do anti-nuclear antibodies decrease thyroid volume? Clin Exp Immunol 2003; 131: 347-354.
14. Venneker GT, Westerhof W, de Vries IJ et al. Molecular heterogeneity of the fourth component of complement (C4) and its genes in vitiligo. J Invest Dermatol 1992; 99: 853-858.
15. Kemp EH, Waterman EA, Gawkrodger DJ, Watson PF, Weetman AP. Autoantibodies to tyrosinase-related - 1 detected in the sera of vitiligo. Br J Dermatol 1998; 139: 798-805.
16. Norris DA, Kissinger RM, Naughton GM, Bystryn JC. Evidence for immunologic mechanisms in human vitiligo: Patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibodydependent cellular cytotoxicity. J Invest Dermatal 1988; 90: 783-789.
17. Kemp E, Gawkrodger D, MacNeil S. Detection of tyrosinase autoantibodiesin patientswith vitiligo using 35S-labeled recombinant human tyrosinase in a radioimmunoassay. J Invest Dermatol 1997; 109: 69-73.
18. Park Y, Kim N, Hann S. Identification of antibody to melanocytes and characterization of vitiligo antigen. J Dermatol Sci 1996; 11: 111-120.
19. Li YL, Yu CL, Yu HS. IgG antimelanocyte antibodies purified from patients with active vitiligo. J Invest Dermatol 2000; 115: 969-973.
20. Kozyr AV, Sashchenko LP, Kolesnikov AV et al. Anti-DNA autoantibodies reveal toxicity to tumor cell lines. Immunol Lett 2002; 80: 41-47.
21. Yu CL, Huang MH, Tsai CY et al. The effect of human polyclonal anti-dsDNA autoantibodies on apoptotic gene expression in cultured rat glomerular mesangial cells. Scand J Rheumatol 1998; 27: 54-60.
22. Alarcon-Segovia D. Antinuclear antibodies: to penetrate or not to penetrate, that was the question. Lupus 2001; 10: 315-318.
23. Adamus G, Machnicki M, Elerding H et al. Antibodies to recover in induce apoptosis of photoreceptor and bipolar cells in vivo. J Autoimmun 1998; 11: 523-533.
24. Schulze K, Becker BF, Schultheiss HP. Antibodies to the ADP/ATP carrier, an autoantigen in myocarditis and dilated cardiomyopathy, penetrate into myocardial cells and disturb energy metabolism in vivo. Circ Res 1989; 64: 179-192.
25. Alarcon-Segovia D, Ruiz-Arguelles A, Fishbein E. Antibody to nuclear ribonucleoprotein penetrates live human mononuclear cells through Fc receptors. Nature 1978; 271: 67-69.
26. Trcka J, Moroi Y, Clynes RA et al. Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo. Immunity 2002; 16: 861-868.
27. Uda H, Takei M, Mishima Y. Immunopathology of vitiligo vulgaris, Sutton's leukoderma and melanoma-associated vitiligo in relation to steroid effects. II. The IgG and C3 deposits in the skin. J Cutan Pathol 1984; 11: 114-124.
28. Abdel-Naser MB, Kruger-Krasagakes S, Krasagakis K et al. Further evidence for involvement of both cell-mediated and humoral immunity in generalized vitiligo. Pigment Cell Res 1994; 7: 1-8.
29. van den Wijngaard RM, Asghar SS, Pijnenborg AC et al. Aberrant expression of complement regulatory proteins, membrane cofactor protein and decay accelerating factor, in the involved epidermis of patients with vitiligo. Br J Dermatol 2002; 146: 80-87.